Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesAdicet Bio Inc

Adicet Bio Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.14 USD 0.09 ( 2.95%)
Last update at 2026-11-09T15:44:00Z
VOLUME
62342
Market Cap
77.38M

Momentum Score

…

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
3.00
Low
3.19
High
52 Week Price Range
6.01
Low
17.44
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Adicet Bio is a clinical-stage immunotherapy company developing engineered allogeneic gamma delta T‑cell therapies and related biologics for cancer. Long-term growth drivers include clinical proof-of-concept for its off‑the‑shelf cell platform, expansion into multiple indications, and potential manufacturing scale-up that could support broader commercialization; these factors appear positioned to attract investors seeking exposure to next‑generation cell therapies.

Principal risks are clinical and regulatory failure, complex and costly manufacturing scale-up, ongoing capital needs that could dilute shareholders, and intense competition; investors should monitor trial readouts and cash runway.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.05
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
24.99M
Debt / Equity
0.09
ROE
-67.55%
Net Debt
-24.18M
ROCE
-71.49%
Diluted EPS TTM
-15.85

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Income before tax -116.80M -117.12M -142.66M -69.79M -69.79M
Net income -116.80M -117.12M -142.66M -67.03M -67.03M
Selling general administrative 22.99M 28.29M 26.53M 26.30M 26.30M
Selling and marketing expenses - - 6.10M - -
Gross profit -6.38M -6.47M -6.10M 24.99M 19.98M
Reconciled depreciation 6.38M 6.47M 6.10M 2.58M 2.58M
Ebit -122.11M -117.12M -132.58M -72.55M -72.55M
Ebitda -115.73M -110.65M -126.48M -69.71M -69.71M
Depreciation and amortization 6.38M 6.47M 6.10M 2.84M 2.84M
Operating income -122.11M -127.61M -132.58M -72.55M -72.55M
Other operating expenses 122.11M 127.61M 132.58M 97.54M 97.54M
Interest expense 0.04M 0.00M 0.03M 0.08M 0.08M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Interest income 5.78M 10.71M 9.98M 3.76M 3.76M
Net interest income 5.74M 10.71M 9.95M 3.68M 3.68M
Income tax expense - - - -2.76M -2.76M
Total revenue 0.00M 0.00M 0.00M 24.99M 24.99M
Total operating expenses 115.73M 127.61M 126.48M 97.54M 97.54M
Cost of revenue 6.38M 6.47M 6.10M - 5.01M
Total other income expense net 5.31M 10.49M -10.08M 2.76M 2.76M
Net income from continuing ops -116.80M -117.12M -142.66M -69.79M -69.79M
Net income applicable to common shares - - - -69.79M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Total assets 192.35M 220.22M 207.29M 330.69M 330.69M
Other current assets 2.05M 3.83M 2.56M 0.38M 0.38M
Total liab 33.15M 33.61M 37.12M 38.35M 38.35M
Total stockholder equity 159.21M 186.61M 170.18M -238.11M -238.11M
Other current liab 13.61M 11.43M 13.44M 12.81M 12.81M
Common stock 0.01M 0.01M 0.00M 0.00M 0.00M
Capital stock 0.01M 0.01M 0.00M 0.00M 0.00M
Retained earnings -614.70M -497.89M -380.77M -238.11M -238.11M
Other liab - - - 0.11M -
Good will - - 0.00M 19.46M 19.46M
Other assets - - 0.00M 1.21M -
Cash 38.92M 56.49M 159.71M 257.66M 257.66M
Total current liabilities 21.53M 19.39M 19.29M 19.71M 19.71M
Net debt -24.18M -39.26M -138.79M -236.63M -236.63M
Short term debt 3.19M 3.13M 3.22M 2.49M 2.49M
Short long term debt total 14.74M 17.23M 20.92M 21.02M 21.02M
Other stockholder equity 773.79M 684.48M 550.94M -0.00M -0.00M
Property plant equipment - - - 48.98M -
Total current assets 160.93M 180.14M 162.27M 261.04M 261.04M
Net tangible assets - - - 272.88M -
Short term investments 119.61M 119.81M - - -
Net receivables 0.34M - - 0.43M 0.43M
Inventory - - - 2.57M 2.57M
Accounts payable 4.74M 4.83M 2.62M 4.40M 4.40M
Accumulated other comprehensive income 0.10M 0.02M 0.00M - 0.00M
Non currrent assets other 0.08M 3.33M 0.82M 1.21M 1.21M
Non current assets total 31.43M 40.08M 45.02M 69.65M 69.65M
Capital lease obligations 14.74M 17.23M 20.92M 21.02M 21.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2023-06-30 2022-12-31
Investments 4.13M -119.24M -4.46M -16.78M -16.78M
Change to liabilities - - - -3.10M -
Total cashflows from investing activities 2.39M -119.24M - -16.78M -
Net borrowings -0.15M 0.00M - - -
Total cash from financing activities 75.25M 111.31M 0.24M 41.51M 41.51M
Change to operating activities - - - 5.65M -
Net income -116.80M -117.12M -142.66M -69.79M -69.79M
Change in cash -17.61M -100.31M -97.94M -20.04M -20.04M
Begin period cash flow 59.40M 159.71M 257.66M 277.69M 277.69M
End period cash flow 41.79M 59.40M 159.71M 257.66M 257.66M
Total cash from operating activities -95.25M -92.38M -93.72M -44.77M -44.77M
Issuance of capital stock 75.17M 110.92M 0.00M 43.36M 43.36M
Depreciation 2.29M 6.47M 6.10M 2.58M 2.58M
Other cashflows from investing activities 145.00M 11.00M - - -
Change to account receivables - - - 0.18M 0.18M
Sale purchase of stock - - -0.15M - -3.23M
Other cashflows from financing activities -0.10M 0.39M -0.15M -1.85M -1.85M
Change to netincome - - - 19.61M -
Capital expenditures 1.74M 1.12M 4.46M 16.78M 16.78M
Change in working capital 1.47M -5.53M 0.25M 2.74M 2.74M
Stock based compensation 14.27M 22.23M 20.26M 17.13M 17.13M
Other non cash items 3.53M 1.57M 56.47M 2.58M 2.58M
Free cash flow -96.98M -93.50M -98.18M -61.55M -61.55M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
ACET
Adicet Bio Inc		 0.09
2.95%		 3.14 - - 9.72 0.52 2.14 -1.21
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 0.34
0.06%		 547.43 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 8.76
0.97%		 913.11 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Adicet Bio Inc

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. The company's lead product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR that targets CD20 for the potential treatment of autoimmune diseases. It also develops ADI-212, a gene-edited and armored clinical candidate that targets prostate-specific membrane antigen. The company was founded in 2014 and is based in Boston, Massachusetts.

131 Dartmouth Street, Boston, MA, United States, 02116

650 503 9095

https://www.adicetbio.com

102

Name Title Year Born
Mr. Chen Schor BA, CPA, CPA, M.B.A., MBA CEO, Pres & Director 1972
Dr. Aya Jakobovits Ph.D. Founder & Independent Director 1953
Mr. Brian Nicholas Harvey Chief Financial Officer 1961
Dr. Francesco Galimi M.D., Ph.D. Chief Medical Officer & Sr. VP 1968
Dr. Donald Healey Chief Technology Officer 1962
Dr. Blake Aftab Ph.D. Sr. VP & Chief Scientific Officer NA
Ms. Amy Locke Head of HR NA
Dr. Nancy L. Boman M.D., Ph.D. Sr. VP & Chief Regulatory Officer NA
Mr. Chen Schor BA, CPA, M.B.A. CEO, President & Director 1972
Dr. Aya Jakobovits Ph.D. Founder & Independent Director 1956

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…